Experimental CAR t therapy targets tough leukemia in first human trial

NCT ID NCT04690595

Ongoing Disease control Sponsor: PeproMene Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new type of immunotherapy called BAFFR-CAR T cells for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to at least two prior treatments. The therapy involves reprogramming a patient's own immune cells to recognize and attack cancer cells. The main goals are to check safety and see if the treatment can shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAFFR-CAR T cells
What this could lead to: If this works, it could offer a new treatment option for patients with B-cell acute lymphoblastic leukemia that has not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 24 participants, so it is not yet known if the treatment is safe or effective. Side effects like cytokine release syndrome and neurotoxicity are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma lymphoblastic lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.